What Is the Prognosis for Lymphoma?

In determining what is the prognosis for lymphoma, it is crucial to first identify which specific lymphoma the patient has. There are, for example 30 types of non-Hodgkin's lymphoma (NHL) and five types of Hodgkin's disease, each with their own progression profile and prognostic outlook. As a very general rule of thumb, Hodgkin lymphomas tend to have higher survival rates, but again, there are a number of other factors that go into that determination.

Aggressiveness

One major classification scheme for prognostic purposes is whether the lymphoma is indolent (slow-growing) or aggressive (fast-growing). The traditional viewpoint is that aggressive cancers are harder to treat because they spread much more easily and quickly to other areas of the body. However, there is a growing movement in oncology the argues that indolent cancers are harder to "cure" than certain fast-growing B-cell lymphomas. The reasoning is that fast-dividing cancer cells are less like the body's own cells, and so are more easily targeted by chemotherapy agents. Also, treating indolent cells is more likely to involve neighboring healthy cells.

Staging and Spread

Lymphoma tends to be graded (staged) on its spread within the body and assigned a number on a scale of I (1) to IV (4). Stage I cancers are easiest to treat and have the best outlook for survival, but it is uncommon to find lymphoma this early because it is an internal cancer. At the other end, stage IV lymphomas have fairly poor prognoses.

B-symptoms

Some lymphomas can be staged more precisely by giving them a number, and then narrowing it down within that stage based on the presence or absence of certain symptoms. These so-called b-lymphoma symptoms are things like night sweats, fever and weight loss, and indicate the cancer is more serious than it would be in a person at the same stage but without noticeable signs.

Age and Sex

The prognosis for lymphoma in younger people is better than in older people. Whenever you see a survival rate of 95 percent, it tends to be among a young, otherwise healthy population.

Women generally have higher survival rates and more positive prognoses than men.

Patient Health

An oncologist may or may not take a patient's current health into account when providing a formal prognosis, but statistically, healthier individuals have higher survival rates for cancer than less healthy ones. Because your immune system can be compromised by both chemotherapy and the cancer itself, starting out healthy gives a person a head start.

When you ask your doctor what is the prognosis for lymphoma, she will walk you through all of the above distinctions and be able to provide (sometimes very precise) estimate of survival rates in your situation.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap